<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001450</url>
  </required_header>
  <id_info>
    <org_study_id>950198</org_study_id>
    <secondary_id>95-C-0198</secondary_id>
    <nct_id>NCT00001450</nct_id>
  </id_info>
  <brief_title>Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC</brief_title>
  <official_title>Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This is a Phase II study of paclitaxel (Taxol R) administered as a 96-hour (4 day) continuous&#xD;
      infusion followed by a bolus of cisplatin for previously untreated patients with stage III/IV&#xD;
      or relapsed non-small cell lung cancer (NSCLC). The goal of this phase II study is to&#xD;
      determine the response rate of this infusional paclitaxel and bolus cisplatin regimen in&#xD;
      patients with advanced NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II study of paclitaxel (Taxol R) administered as a 96-hour (4 day) continuous&#xD;
      infusion followed by a bolus of cisplatin for previously untreated patients with stage III/IV&#xD;
      or relapsed non-small cell lung cancer (NSCLC). The goal of this phase II study is to&#xD;
      determine the response rate of this infusional paclitaxel and bolus cisplatin regimen in&#xD;
      patients with advanced NSCLC. In addition, the plasma levels of paclitaxel will be measured,&#xD;
      and the in vitro paclitaxel chemosensitivity of the tumor cells from as many patients as&#xD;
      possible will be determined. This will allow further study of the relationship between in&#xD;
      vitro drug sensitivity, achievable plasma concentrations of paclitaxel, and patients'&#xD;
      response to therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1995</start_date>
  <completion_date>June 2000</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>58</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Lung Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Histologically confirmed non-small cell lung cancer, including: Squamous cell carcinoma,&#xD;
        Adenocarcinoma, Large cell carcinoma, Mixed histologies in the absence of a predominant&#xD;
        small cell component.&#xD;
&#xD;
        Eligible Stages Include:&#xD;
&#xD;
        Stage IV, Stage IIIA/B ineligible for resection or radiotherapy, Postsurgical recurrence&#xD;
        that is histologically or cytologically proven.&#xD;
&#xD;
        CNS Metastases Allowed Provided:&#xD;
&#xD;
        Radiotherapy completed prior to entry.&#xD;
&#xD;
        No requirement for concurrent steroids.&#xD;
&#xD;
        No carcinomatous meningitis.&#xD;
&#xD;
        No epidural metastases.&#xD;
&#xD;
        Measurable disease not required.&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic Therapy: Not specified.&#xD;
&#xD;
        Chemotherapy: No prior chemotherapy for lung cancer.&#xD;
&#xD;
        Endocrine Therapy: Not specified.&#xD;
&#xD;
        Radiotherapy: No prior chest irradiation for lung cancer.&#xD;
&#xD;
        Surgery: Prior surgery allowed.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age: 18 and over.&#xD;
&#xD;
        Performance Status: ECOG 0-2.&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
        Absolute granulocyte count greater than 2,000.&#xD;
&#xD;
        Platelet count greater than 100,000.&#xD;
&#xD;
        Hepatic: Bilirubin no greater than 1.5 mg/dL.&#xD;
&#xD;
        Renal: Creatinine no greater than 1.5 mg/dL.&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
        No CHF unless fully compensated.&#xD;
&#xD;
        No second- or third-degree heart block.&#xD;
&#xD;
        No uncontrolled, symptomatic atrial dysrhythmia except sinus bradycardia.&#xD;
&#xD;
        No sustained ventricular tachycardia.&#xD;
&#xD;
        No MI within 3 months.&#xD;
&#xD;
        OTHER:&#xD;
&#xD;
        No uncontrolled infection unless due to an obstructed bronchus.&#xD;
&#xD;
        No major psychiatric problems requiring hospitalization.&#xD;
&#xD;
        No psychotropic medications such as phenothiazines.&#xD;
&#xD;
        No contraindication to transfusion, if required.&#xD;
&#xD;
        No second malignancy within 5 years except: Nonmelanomatous skin cancer.&#xD;
&#xD;
        In situ cervical cancer.&#xD;
&#xD;
        No pregnant or nursing women.&#xD;
&#xD;
        Effective contraception required of fertile patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 1999</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Chemotherapy</keyword>
  <keyword>In Vitro Testing</keyword>
  <keyword>Infusional</keyword>
  <keyword>Lung Neoplasm</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

